Researchers from Tempus have partnered with the UCLA Mattel Children’s Hospital to expand the TIME Trial Program and help pediatric patients access clinical trials. With the addition of UCLA, TIME will expand trial access to pediatric and adolescent/young adult (AYA) patients for the first time.

Dr. Noah Federman, the Nancy and Jonathan Glaser Family Endowed Chair for Pediatric Sarcomas will be acting as the principal investigator for UCLA. “We are thrilled to roll out the Tempus TIME for Kids program at UCLA. This is a huge step to prioritizing precision oncology clinical trials in children, and accelerating time to study activation and enrollment in under two weeks, which is unprecedented,” said Dr. Federman. “Additionally, bringing an existing targeted therapeutic oncology clinical trial to the patient rather than making the patient travel to the site of the clinical trial is a critical step in making clinical trials more patient and community focused.” 

The TIME Trial Program is a two-sided research network which includes 200+ institutions and provides them access to a portfolio of biomarker-based clinical trials. When a patient is matched to a specific trial, TIME network sites are able to rapidly open the trial in a just-in-time format and begin treating the patient on trial within two weeks.